Marshall Wace LLP Increases Stake in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Marshall Wace LLP boosted its stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 99.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 132,286 shares of the company's stock after buying an additional 65,994 shares during the period. Marshall Wace LLP owned approximately 0.81% of Sensus Healthcare worth $915,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new position in shares of Sensus Healthcare during the fourth quarter valued at $27,000. Barclays PLC purchased a new position in Sensus Healthcare in the fourth quarter worth about $35,000. IFP Advisors Inc purchased a new position in Sensus Healthcare in the fourth quarter worth about $95,000. NewEdge Advisors LLC bought a new position in shares of Sensus Healthcare in the fourth quarter worth approximately $109,000. Finally, CreativeOne Wealth LLC bought a new stake in shares of Sensus Healthcare during the fourth quarter valued at approximately $155,000. Hedge funds and other institutional investors own 25.30% of the company's stock.

Sensus Healthcare Stock Performance

Shares of SRTS stock remained flat at $4.33 on Friday. The stock had a trading volume of 129,345 shares, compared to its average volume of 310,667. Sensus Healthcare, Inc. has a 52-week low of $3.53 and a 52-week high of $9.33. The firm has a market cap of $71.42 million, a PE ratio of 10.83 and a beta of 1.11. The stock's 50-day simple moving average is $4.63 and its 200 day simple moving average is $6.27.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. As a group, sell-side analysts predict that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on the company. HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of Sensus Healthcare in a research note on Friday, April 4th. Lake Street Capital reduced their price objective on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, March 11th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.